Humacyte, Inc.

Humacyte develops and manufactures off-the-shelf, implantable bioengineered human tissues designed for treating diseases across multiple therapeutic areas. The company's proprietary technology platform engineers human acellular vessels (HAVs) that can be implanted without triggering foreign body responses or immune rejection. This approach addresses a significant limitation in current vascular replacement therapies, which often rely on synthetic materials or autografts with inherent drawbacks.

The company's product portfolio targets the vascular repair, reconstruction, and replacement market, with applications including vascular trauma repair, arteriovenous access for hemodialysis, peripheral arterial disease treatment, pediatric heart surgery, and coronary artery bypass grafting. Humacyte is also developing HAVs for cellular therapy delivery, specifically for pancreatic islet cell transplantation in Type 1 diabetes treatment. The company operates as a single reportable segment focused on tissue engineering and regenerative medicine.

Based in Durham, North Carolina, Humacyte operates with approximately 218 full-time employees. The company was founded in 2004 and is incorporated in Delaware, with its common stock listed on Nasdaq. The organization remains in clinical development and commercialization stages for its tissue engineering platform.